Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:GW_Pharmaceuticals
|
| gptkbp:acquisitionYear |
2021
|
| gptkbp:CEO |
gptkb:Bruce_Cozadd
|
| gptkbp:countryOfOrigin |
gptkb:United_States
|
| gptkbp:focusArea |
neuroscience
oncology sleep medicine |
| gptkbp:foundedIn |
2003
|
| gptkbp:founder |
gptkb:Bruce_Cozadd
|
| gptkbp:headquartersLocation |
gptkb:Dublin,_Ireland
gptkb:Palo_Alto,_California |
| https://www.w3.org/2000/01/rdf-schema#label |
Jazz Pharmaceuticals
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:netRevenue2022 |
$3.7 billion
|
| gptkbp:notableEmployee |
gptkb:Bruce_Cozadd
|
| gptkbp:numberOfEmployees |
~2,800
|
| gptkbp:product |
gptkb:Epidiolex
gptkb:Xyrem gptkb:Sunosi gptkb:Zepzelca |
| gptkbp:publiclyTraded |
yes
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:JAZZ
|
| gptkbp:therapeuticArea |
oncology
rare diseases central nervous system disorders |
| gptkbp:website |
https://www.jazzpharma.com/
|
| gptkbp:bfsParent |
gptkb:GW_Pharmaceuticals
gptkb:PhRMA |
| gptkbp:bfsLayer |
6
|